Search

Dengue, an arbovirus, is a public health treat in the tropics and sub-tropical climates worldwide. The disease incidence has grown dramatically worldwide, with an estimated 390 million dengue virus infection per year. Dengue has distinct epidemiological patterns which are associated with the four virus serotypes. All four serotypes can co-circulate within a region, in which a number of regions are hyperendemic for all 4 serotypes. Currently, there are no specific treatment or vaccine for the disease. Dengue prevention depends on vector control measures and early interventions. The COVID-19 pandemic has placed immense pressure on health care and management systems worldwide. During the COVID-19 pandemic, the situation was aggravated by the simultaneous dengue outbreaks, that has led to a double burden which has further impacted the healthcare sector, particularly in resource limited settings. This review article will focus on dengue epidemics during the COVID-19 pandemic and discuss on recent findings on immunological cascades between dengue and COVID-19 and, the impact on vaccine development.

Dengue fever is a painful, debilitating, arthropod-borne disease. In recent years, dengue endemic regions have markedly expanded in the tropics, South-east Asia, and the Americas. Epidemics have also been re- ported in subtropical regions of East Asia and Europe. Factors including an increase in the frequency of international travel and period of stay, increase in population density, and global warming, are hypothesized to be associated with the rapid spread of dengue. Approximately 4 billion people are estimated to be infected with the virus each year'). However, there are no effective therapeutics nor clinically approved vaccine for dengue in the region. In 2014, a local dengue outbreak involving 162 cases occurred in Japan2). With the increasing annual numbers of imported dengue cases, there is a need to strengthen and improve the capacity for disease control and prevention. [Review].

A 31-year-old Japanese female had stayed in Australia from January to May 2013. She presented with a sudden onset of left ankle and right knee arthralgia in March but neither fever nor rash was present. As her arthralgia persisted, she visited our hospital upon her return to Japan in May. When she came to our hospital, she complained of left ankle and right knee pain, but no arthritis findings. Laboratory findings were also within normal ranges. Ross River virus (RRV) antibody levels were examined as she was suspected of having contracted the disease in Australia. RRV IgG antibody and IgM antibody were positive, and the patient was confirmed as a case of acute RRV disease. RRV disease is endemic in Australia, but there are no prior reports of the disease in Japan. This is the first case of RRV disease confirmed in Japan. Typical symptoms of RRV disease include arthralgia, fever, and rash. Our patient had only arthralgia. With the increase in the number of travelers and length of stay in RRV endemic regions, health care providers need to consider the disease in their differential diagnosis, among returning travelers with arthralgia, fever, rash and a travel history to RRV-endemic regions.